Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Apr;77(8):1311–1317. doi: 10.1038/bjc.1998.218

Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.

R Henriksson 1, S Nilsson 1, S Colleen 1, P Wersäll 1, M Helsing 1, R Zimmerman 1, K Engman 1
PMCID: PMC2150170  PMID: 9579838

Abstract

Metastatic renal cell carcinoma (RCC) has a poor prognosis. Conventional treatment strategies, including chemotherapy and hormonal therapy, have limited value. Although encouraging results have been achieved in terms of objective response using immunological manipulations, no conclusive studies yet exist with a controlled comparative evaluation of survival. Therefore, the present study was undertaken, which compared one of the present (and presumed best) treatments, interleukin 2/interferon-alpha (IL-2/IFN-alpha) and tamoxifen, with a control arm of tamoxifen only. Tamoxifen has been shown to potentiate in vivo anti-tumour activity of IL-2, and because of its non-toxic behaviour it was included in both groups. The study was open, randomized and included seven institutions in Sweden. The patients were stratified according to the different centres involved. An interim analysis was planned when a minimum of 100 patients were evaluable. The 128 patients finally included had a histologically documented metastatic RCC, with a life expectancy of more than 3 months, a performance status WHO 0-2 and no prior chemo- or immunotherapy. Informed consent was obtained from each patient. The patients randomized to the control arm (n = 63) received only tamoxifen 40 mg p.o. daily for at least 1 year or until progression. The patients (n = 65) randomized to biotherapy received subcutaneous recombinant IL-2, leucocyte IFN-alpha in a treatment cycle of 42 days, as well as tamoxifen p.o. In the absence of undue toxicity or disease progression, these patients received one additional treatment cycle of 42 days followed by maintenance treatment, consisting of 5 days therapy every 4 weeks, for 1 year, or until proven progression. Only two patients in the tamoxifen-only group received immunotherapy when the disease progressed, but without any beneficial effect. All patients received appropriate local treatment when indicated. The interim analysis demonstrated no survival advantage for either group, and therefore further inclusion of patients was stopped. The median follow-up was 11 months (range 0.4-48 months). The final survival analysis showed no significant differences between the two treatment arms in so far as comparison from the day of diagnosis of primary disease, from the day of first evidence of metastatic spread, or from the onset of treatment. This was valid both when the evaluation was performed with regard to intention to treat and when the analysis was directed only to patients that managed at least one treatment cycle (42 days) of IL-2/IFN-alpha. The adverse effects were more pronounced in the IL-2/IFN-alpha group. Although the number of patients is limited, the results raise doubt concerning immunotherapy with IL-2 and IFN-alpha as a routine treatment in the management of advanced RCC. The difference in cost of drugs and health care (drug costs per patient: IL-2/IFN-alpha $27000 vs tamoxifen $360) as well as adverse effects caused by IL-2/IFN-alpha are also factors of importance. The study emphasizes the need for more effort to find the 'optimal schedule' of immunotherapy, as well as the need for randomized controlled studies before approval of a new treatment in the routine setting.

Full text

PDF
1317

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahren B., Engman K., Lindblom A. Treatment of malignant midgut carcinoid with a highly purified human leukocyte alpha-interferon. Anticancer Res. 1992 Jan-Feb;12(1):129–133. [PubMed] [Google Scholar]
  2. Atzpodien J., Körfer A., Franks C. R., Poliwoda H., Kirchner H. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet. 1990 Jun 23;335(8704):1509–1512. doi: 10.1016/0140-6736(90)93039-r. [DOI] [PubMed] [Google Scholar]
  3. Atzpodien J., Lopez Hänninen E., Kirchner H., Bodenstein H., Pfreundschuh M., Rebmann U., Metzner B., Illiger H. J., Jakse G., Niesel T. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol. 1995 Feb;13(2):497–501. doi: 10.1200/JCO.1995.13.2.497. [DOI] [PubMed] [Google Scholar]
  4. Besana C., Borri A., Bucci E., Citterio G., Di Lucca G., Fortis C., Matteucci P., Tognella S., Tresoldi M., Baiocchi C. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon. Eur J Cancer. 1994;30A(9):1292–1298. doi: 10.1016/0959-8049(94)90176-7. [DOI] [PubMed] [Google Scholar]
  5. Elson P. J., Witte R. S., Trump D. L. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res. 1988 Dec 15;48(24 Pt 1):7310–7313. [PubMed] [Google Scholar]
  6. Facendola G., Locatelli M. C., Pizzocaro G., Piva L., Pegoraro C., Pallavicini E. B., Signaroldi A., Meregalli M., Lombardi F., Beretta G. D. Subcutaneous administration of interleukin 2 and interferon-alpha-2b in advanced renal cell carcinoma: a confirmatory study. Br J Cancer. 1995 Dec;72(6):1531–1535. doi: 10.1038/bjc.1995.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fosså S. D., Martinelli G., Otto U., Schneider G., Wander H., Oberling F., Bauer H. W., Achtnicht U., Holdener E. E. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol. 1992 Apr;3(4):301–305. doi: 10.1093/oxfordjournals.annonc.a058185. [DOI] [PubMed] [Google Scholar]
  8. Harris D. T. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin Oncol. 1983 Dec;10(4):422–430. [PubMed] [Google Scholar]
  9. Katz S. E., Schapira H. E. Spontaneous regression of genitourinary cancer--an update. J Urol. 1982 Jul;128(1):1–4. doi: 10.1016/s0022-5347(17)52725-1. [DOI] [PubMed] [Google Scholar]
  10. Kellokumpu-Lehtinen P., Jantunen I., Flander M., Johansson R., Nordman E. Combined interferon and vinblastine treatment in advanced renal cell cancer. Acta Oncol. 1995;34(7):975–977. doi: 10.3109/02841869509127219. [DOI] [PubMed] [Google Scholar]
  11. Kim B., Warnaka P., Konrad C. Tamoxifen potentiates in vivo antitumor activity of interleukin-2. Surgery. 1990 Aug;108(2):139–145. [PubMed] [Google Scholar]
  12. Lopez Hänninen E., Kirchner H., Atzpodien J. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996 Jan;155(1):19–25. [PubMed] [Google Scholar]
  13. Motzer R. J., Schwartz L., Law T. M., Murphy B. A., Hoffman A. D., Albino A. P., Vlamis V., Nanus D. M. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol. 1995 Aug;13(8):1950–1957. doi: 10.1200/JCO.1995.13.8.1950. [DOI] [PubMed] [Google Scholar]
  14. Oliver R. T., Nethersell A. B., Bottomley J. M. Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma. Br J Urol. 1989 Feb;63(2):128–131. doi: 10.1111/j.1464-410x.1989.tb05147.x. [DOI] [PubMed] [Google Scholar]
  15. Oliver R. T. Renal cell cancer: is there long-term survival advantage from cytokine treatment? Eur J Cancer. 1994;30A(9):1214–1216. doi: 10.1016/0959-8049(94)90159-7. [DOI] [PubMed] [Google Scholar]
  16. Osband M. E., Lavin P. T., Babayan R. K., Graham S., Lamm D. L., Parker B., Sawczuk I., Ross S., Krane R. J. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet. 1990 Apr 28;335(8696):994–998. doi: 10.1016/0140-6736(90)91064-h. [DOI] [PubMed] [Google Scholar]
  17. Philip T., Negrier S., Lasset C., Coronel B., Bret M., Blay J. Y., Merrouche Y., Carrie C., Kaemmerlen P., Chauvin F. Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. Br J Cancer. 1993 Nov;68(5):1036–1042. doi: 10.1038/bjc.1993.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Prümmer O. Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer. 1993 Mar 1;71(5):1828–1834. doi: 10.1002/1097-0142(19930301)71:5<1828::aid-cncr2820710518>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  19. Rosenberg S. A., Lotze M. T., Yang J. C., Topalian S. L., Chang A. E., Schwartzentruber D. J., Aebersold P., Leitman S., Linehan W. M., Seipp C. A. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993 Apr 21;85(8):622–632. doi: 10.1093/jnci/85.8.622. [DOI] [PubMed] [Google Scholar]
  20. Savage P. D. Renal cell carcinoma. Curr Opin Oncol. 1995 May;7(3):275–280. doi: 10.1097/00001622-199505000-00013. [DOI] [PubMed] [Google Scholar]
  21. Stahl M., Schmoll E., Becker H., Schlichter A., Hoffmann L., Wagner H., Possinger K., Müller W., Köllermann M., Weidenhammer W. Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. Semin Oncol. 1991 Apr;18(2 Suppl 4):33–37. [PubMed] [Google Scholar]
  22. Steineck G., Strander H., Carbin B. E., Borgström E., Wallin L., Achtnich U., Arvidsson A., Söderlund V., Näslund I., Esposti P. L. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial. Acta Oncol. 1990;29(2):155–162. doi: 10.3109/02841869009126537. [DOI] [PubMed] [Google Scholar]
  23. Wagstaff J., Baars J. W., Wolbink G. J., Hoekman K., Eerenberg-Belmer A. J., Hack C. E. Renal cell carcinoma and interleukin-2: a review. Eur J Cancer. 1995;31A(3):401–408. doi: 10.1016/0959-8049(94)00494-p. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES